Vice President, Early Clinical Development, Radiopharmaceutical Therapies

Responsibilities

• Design and execute Phase 0/1 trials for radiopharmaceutical therapies
• Lead translation of preclinical pharmacology to First-in-Human dosing strategies
• Collaborate with medical physicists on radiation dosimetry in clinical protocols
• Act as primary clinical expert for global health authority meetings and IND submissions
• KOL Collaboration: Build a network of academic and nuclear medicine specialists for strategic alignment
• Portfolio Strategy: Lead strategies for early clinical development assets at RayzeBio
• Mentorship: Mentor RayzeBio asset teams and serve as a cross-functional leader

Qualifications

• Advanced Degree: MD or PhD in Oncology, Nuclear Medicine, or related fields; MD/PhD preferred
• Clinical Depth: 12+ years of drug development experience, specifically in early-phase clinical protocols for radiopharmaceuticals
• Led clinical and cross-functional teams in a biotech setting
• Experience designing dose-escalation studies for radioactive drugs
• Knowledge of implementing 'image-then-treat' approaches in clinical settings
• Proficient in clinical dosimetry protocols ensuring patient safety and compliance
• Strong commitment to understanding and improving patient outcomes in cancer therapeutics

Benefits

• Innovative work environment at a leading biotech company
• Opportunity for collaboration with top oncology leaders and research teams
• Focus on transformative cancer therapies that improve patient survival
• Leadership role with significant impact on clinical development strategy
• Possibility to lead cross-functional teams in a dynamic setting

Pay

$341,360 – $413,648 annually

Schedule

Remote - US based candidates only, no visa sponsorship available